Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639662/ |